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Abstract
Background: Rates of surgery and adjuvant therapy for breast cancer vary widely between breast units. This may contribute to
differences in survival. This cluster RCT evaluated the impact of decision support interventions (DESIs) for older women with breast
cancer, to ascertain whether DESIs influenced quality of life, survival, decision quality, and treatment choice.
Methods: A multicentre cluster RCT compared the use of two DESIs against usual care in treatment decision-making in older women
(aged at least 70 years) with breast cancer. Each DESI comprised an online algorithm, booklet, and brief decision aid to inform choices
between surgery plus adjuvant endocrine therapy versus primary endocrine therapy, and adjuvant chemotherapy versus no chemother-
apy. The primary outcome was quality of life. Secondary outcomes included decision quality measures, survival, and treatment choice.
Results: A total of 46 breast units were randomized (21 intervention, 25 usual care), recruiting 1339 women (670 intervention,
669 usual care). There was no significant difference in global quality of life at 6 months after the baseline assessment on intention-
to-treat analysis (difference –0.20, 95 per cent confidence interval (C.I.) –2.69 to 2.29; P¼ 0.900). In women offered a choice of primary
endocrine therapy versus surgery plus endocrine therapy, knowledge about treatments was greater in the intervention arm (94 versus
74 per cent; P¼ 0.003). Treatment choice was altered, with a primary endocrine therapy rate among women with oestrogen receptor-
positive disease of 21.0 per cent in the intervention versus 15.4 per cent in usual-care sites (difference 5.5 (95 per cent C.I. 1.1 to 10.0)
per cent; P¼ 0.029). The chemotherapy rate was 10.3 per cent at intervention versus 14.8 per cent at usual-care sites (difference –4.5
(C.I. –8.0 to 0) per cent; P¼ 0.013). Survival was similar in both arms.
Conclusion: The use of DESIs in older women increases knowledge of breast cancer treatment options, facilitates shared decision-
making, and alters treatment selection.
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Trial registration numbers: EudraCT 2015-004220-61 (https://eudract.ema.europa.eu/), ISRCTN46099296 (http://www.controlled-trials.
com).
Introduction
Breast cancer outcomes for older women are inferior to those of
younger women because of the later stage at diagnosis and high
rates of non-guideline-concordant care1–3. The UK lags behind
other high-income European countries in survival outcomes for
older women4. Age-related variation in practice between UK units
is widespread owing to a lack of guidelines stratified by health and
fitness and variation in clinician opinion5–7. Omission of surgery in
favour of primary endocrine therapy occurs in up to 40 per cent of
women over 70 years of age in the UK8, despite evidence of sub-
stantially improved rates of local control9 and a small long-term
survival benefit for women who have surgery8,10. Surgery is, how-
ever, not always appropriate and may cause harm if used unneces-
sarily in very frail patients, as shown in a US study11 in which
nursing home residents with breast cancer had high rates of mor-
bidity, mortality, and functional decline following surgery.
Rates of adjuvant chemotherapy are also significantly lower in
women aged over 70 years. Sixty-one per cent of patients aged
50–69 years with oestrogen receptor (ER)-negative disease receive
chemotherapy versus 23 per cent of those aged over 70 years.
Similar differences in chemotherapy rates are seen in women
with ER-positive disease3.
The potential risks of adverse events from surgery12 or chemo-
therapy13,14 are increased in older patients, but breast cancer-
specific and overall survival benefits exist for appropriately
selected women. There is a lack of guidance on which thresholds
should be applied in making these decisions. The International
Society of Geriatric Oncology/European Society of Breast Cancer
Specialists15 guidelines recommend surgery if the woman is fit,
but patient automomy and right to choose must be respected if
older women elect to have non-guideline-concordant care.
Decision-making in cancer care is now supported by a number of
online algorithms, which permit stratification of treatment accord-
ing to parameters such as stage and tumour biology, but no such
tool exists for the choice of breast surgery plus adjuvant therapies
versus primary endocrine therapy alone in older women. In addition,
the tools available to support chemotherapy decision-making are
based on trial data from younger women16–18 and typically do not
take into account co-morbidities, so may be less applicable to older
women19,20.
This study builds on previous work to develop decision
support interventions (DESIs) to aid in shared decision-making by
older women with breast cancer. These DESIs include two book-
lets21, brief decision aids, and a validated online decision algo-
rithm (Age Gap Decision ToolVC ; https://agegap.shef.ac.uk/), based
on UK cancer registry survival data, adjusted for co-morbidities
and frailty8,22. The online tool produces personalized survival
outcomes for women aged 70 years or above with operable breast
cancer according to fitness, frailty, stage, treatment choice, and
disease biology. The DESIs developed for this study used the pre-
ferred informational content, format, terminology, and media for
women over 70 years of age, and were piloted extensively in this
age group21,23,24.
The present study evaluated the impact of these DESIs on qual-
ity of life (QoL), survival, breast cancer treatment choice, and deci-
sion quality measures, in a multicentre cluster RCT (cRCT) across
England and Wales. Trial centres were already recruiting to a mul-
ticentre, prospective cohort study of treatment and outcomes in
women aged 70 years or above with early breast cancer (Age Gap
study), which collected detailed data on baseline characteristics (a
comprehensive geriatric assessment), treatments, and outcomes.
This cRCT was nested within the Age Gap study. The trial was
cluster randomized because the materials could not feasibly be
given to, or withheld from, individually randomized clinicians or
patients. Recruiting sites were randomized to either continue with
usual care or were given training in the use of, and access to, the
DESIs. Cluster randomization was stratified by primary endocrine
therapy and chemotherapy rates to avoid bias.
The aims of the study were to evaluate the effects of the DESIs
on patients’ QoL, survival (at a median follow-up of 36 months),
decision quality, and on the two key treatment choices: surgery
plus adjuvant endocrine therapy versus primary endocrine
therapy, and adjuvant chemotherapy versus no chemotherapy.
Secondary aims included assessment of the effects on patients’
coping and decision regret.
Methods
This was a multicentre, parallel-group, pragmatic, cRCT nested
within a larger cohort study of older women (aged over 70 years)
with early breast cancer (Age Gap study). Clusters (individual breast
units) were randomized to either normal decision-making practices
(relating to choice of surgery plus adjuvant endocrine therapy versus
primary endocrine therapy, or whether to have adjuvant chemo-
therapy after surgery) or to training and use of the DESIs (Fig. 1).
Trial reporting followed the cluster trial extension of the CONSORT
guidelines25. The protocol for the trial has been published26. Ethics
(IRAS:12LO1808) and research governance approvals were obtained.
The trial was registered with EudraCT (2015-004220-61) and the
ISRCTN registry (ISRCTN46099296).
Recruitment sites
The study recruited from 46 breast units (Table S1) in England and
Wales between December 2015 and June 2018.
Eligibility and exclusion criteria
Inclusion criteria were women aged 70 years or above at diagno-
sis with primary operable invasive breast cancer (TNM categories
T1–3 N0–1 M0), who were able to read English. Exclusion criteria
were: inoperable, locally recurrent or metastatic breast cancer;
and a history of previous invasive breast cancer within 5 years.
Randomization
Centres (breast units) were subjected to 1 : 1 block randomiza-
tion, stratified by high or low current primary endocrine therapy
and chemotherapy rates. Centres were randomized either to
have access to the DESIs and training in their use, or to continue
with usual care.
Trial interventions
The DESIs included an online tool, booklet, and brief decision
aid to support the decision regarding surgery plus adjuvant
endocrine therapy versus primary endocrine therapy, or adjuvant
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chemotherapy versus no chemotherapy. The development of
these tools has been reported previously21–24,27 and is summa-
rized in Fig. S1.
Training package
Staff from usual-care and intervention sites attended a site
initiation visit to explain the trial. Intervention sites were also
given specific face-to-face or online training in the use of the two
DESIs to support shared decision-making.
Trial outcomes
Data were collected at baseline, 6 weeks, and 6 months (Table S2).
Primary endpoint
QoL was assessed at 6 months after diagnosis using the generic
cancer QoL measure, the European Organisation for the Research
and Treatment of Cancer (EORTC) QoL questionnaire (QLQ)
C3028. The primary outcome was the global health status score
(questions 29 and 30) of the C30 at 6 months. Patients had the
option to decline completion of QoL forms and the various
decision quality forms if felt to be burdensome, and patients with
significant cognitive impairment (recruited by proxy) were not
expected to complete them.
Secondary outcome measures
Data from EORTC QLQ-C30, QLQ-BR23 (breast cancer-specific
QoL)29, and QLQ-ELD14 (older person-specific QoL30) question-
naires were collected at 6 weeks and 6 months, and compared
across all domains between usual-care and intervention centres.
Treatment choices were evaluated in certain subgroups of
women (rates of surgery plus adjuvant endocrine therapy versus
primary endocrine therapy in women with ER-positive cancers,
chemotherapy rates in all patients and those whose cancer had a
high recurrence risk). The appropriateness of treatment choice
was assessed by comparison of the characteristics of allocated
women (age, fitness, frailty, tumour characteristics) and survival
metrics. To facilitate this assessment, all patients in the study,
not just those who were actually offered the relevant choice,
were included in the analysis.
Patient knowledge, if offered a choice of relevant treatments,
was assessed using a bespoke eight-item questionnaire. Correct
responses were assigned a score of 1, whereas incorrect and
‘unsure’ responses scored 0. Scores were measured before and
6 weeks after decision-making (Table S2).
CollaboRATE, a validated three-item shared decision-making
measure31, was scored by patients on a 10-point scale ranging
from 0 (no effort at all) to 9 (every effort made) to rate efforts to
facilitate shared decision-making. Scores were summed and mul-
tiplied by 3.704 to transform into a scale of 0–100. This was ap-
plied to all women offered a choice and assessed at baseline after
decision-making but before treatment commenced (Table S2).
Five items on a decision regret scale32 were rated from 1
(strongly agree) to 5 (strongly disagree); examples are ‘It was the
right decision’ and ‘The choice did me a lot of harm’. This was
given to all women offered a choice, and assessed at 6 weeks and
6 months after decision-making (Table S2).
The six-item Spielberger Short State–Trait Anxiety Inventory
(STAI)33 was administered before treatment, and at 6 weeks and
6 months after decision-making (Table S2).
Women were asked to complete the Brief Illness Perceptions
Questionnaire (BIPQ)34, a nine-item questionnaire measuring
cognitive and emotional representations of cancer, at 6 weeks
and 6 months after decision-making (Table S2).
Coping strategies in response to facing cancer treatment
decisions were assessed using Brief COPE35 6 weeks and 6 months
after decision-making (Table S2).
Overall and breast-cancer specific survival were derived from
UK cancer registry returns (downloaded February 2020, median
survival 36 months).
The study also collected data on the following baseline and
treatment characteristics: age, Charlson Co-morbidity Index
score36, Activities of Daily Living (ADL)37 and Instrumental ADL38,
the Mini Mental State Examination score39, the abridged Patient
Generated Subjective Global Assessment40,41, tumour stage42,
tumour grade and biotype, and treatment.
Use of the online tool by clinicians was evaluated using an
integrated registration system for number and duration of log-ins
at each site. Information on use of the DESIs was collected
directly from the case report form about the consultation.
Process evaluation
A formal process evaluation of the dose, reach, fidelity,
adaptations, and participants’ responses to the DESIs was under-
taken alongside the trial, and is in submission for publication
separately.
46 UK Breast Units already
recruiting to Age Gap
cohort study
Intervention offered as
standard care regardless of
trial recruitment
Staff training in use of
online tool, booklet, and
brief decision aid plus trial
initiation
Access to primary ET versus surgery
booklet, brief decision aid,
and online tool for all





Patients facing parimary ET versus
Surgery+ET decision counselled as
normal
Access to chemotherapy versus no
chemotherapy booklet, brief
decision aid, and online tool













outcomesSham staff training (simple
trial overview with no access
to DESIs)
Usual care
Fig. 1 Design of cluster RCT
DESI, decision support intervention; ET, endocrine therapy.






/bjs/advance-article/doi/10.1093/bjs/znab005/6182547 by guest on 26 M
arch 2021
Data monitoring and ethics
Source data verification was performed for 10 per cent of
patients. An independent data monitoring and ethics committee
reviewed the trial every 3–6 months.
Statistical analysis
The sample size calculation was based on the primary endpoint:
global health status QoL score (questions 29 and 30 of EORTC
QLQ-C30) at 6 months. It was assumed that 50 breast units would
be randomized and would recruit a set number of women per
cluster43, based on a standard deviation of 21 for women aged
70 years or more with breast cancer, with a clinically significant
difference set at 7 points (medium standardized effect size of
0.33)44. An intracluster correlation estimate of 0.03 with 90 per
cent power, 5 per cent significance, and 20 per cent loss to follow-
up yielded a sample size requirement of 50 clusters and
650 patients (13 per cluster; 325 per group).
QoL outcomes were analysed using a general linear model,
with coefficients estimated by generalized estimating equations
with robust standard errors, and an exchangeable correlation
matrix to allow for the clustered nature of the data. Survival was
analysed using Cox proportional hazards regression with site
clustering incorporated via a shared frailty model. Survival time
was censored on 30 February 2020. Sites with fewer than 10 par-
ticipants were combined into one cluster for these analyses.
Treatment decision was tabulated by arm and visualized using
funnel plots45. QoL, survival, and treatment choice were analysed
on an intention-to-treat basis. QoL and survival analyses were re-
peated on a planned per-protocol basis among patients who were
offered a treatment choice and excluding intervention sites that
did not adopt the Age Gap tools. Measures of decision quality and
knowledge were confined to women who were offered a relevant
treatment choice. Other outcomes are presented descriptively.
Time trends for the percentage of patients opting for primary
endocrine therapy and chemotherapy compared with historical
practice in the same unit (recorded from February 2013 for the
cohort study in which the cRCT was nested) were presented
visually using a Lowess smoother46.
Results
Training in and use of DESIs in intervention sites
Training in DESI use was received by 229 healthcare professionals
at intervention sites, with 44 attending a 2-h workshop and their
colleagues completing on-site training (lasting 15–120 (median
60) min). An educational video was also available online, which
was viewed 227 times.
Site randomization and patient recruitment
The trial randomized 48 centres (23 to DESI, 25 to usual care)
(Table S1). Two clusters dropped out before recruiting any women
(both in intervention arm), leaving 46 clusters (21 intervention,
25 usual care) in the intention-to-treat analysis. The 46 clusters
recruited 1339 patients (670 intervention, 669 usual care) be-
tween 1 December 2015 and 6 June 2018 (Fig. 2).
The median cluster size was 26 (range 1–96); three clusters
recruited fewer than five patients and seven centres fewer than
10. QoL form completion was optional and this resulted in a total
of 441 patients (in the 21 clusters) in the intervention arm com-
pleting baseline QoL forms and 469 (in the 25 clusters) in the
usual-care arm. Not all of these completed the 6-month follow-
up forms; 359 QoL forms were available at 6 months in the inter-
vention arm and 389 in the usual-care arm (Fig. 2).
The median age of participants was 77 (i.q.r. 70–96) years.
Patients in the intervention and usual-care arms were well
matched for baseline health and fitness, tumour stage, and biol-
ogy (Table 1).
Patients offered treatment choice and use of
DESIs
A total of 319 women were offered a choice of surgery plus endo-
crine therapy versus primary endocrine therapy alone.
Online algorithm usage data showed that 221 healthcare pro-
fessionals were given log-in codes and 494 individual log-in
events were recorded to the DESI tool. Approximately half of in-
tervention sites used the DESI tool regularly and the other half
rarely. Use of the DESI tool for surgery plus endocrine therapy
versus primary endocrine therapy alone was much greater than
that for the chemotherapy DESI, reflecting low rates of discussion
about chemotherapy among older women. A total of 209 patients
had a discussion about surgery plus endocrine therapy versus pri-
mary endocrine therapy alone, and 27 a discussion about having
chemotherapy or not. The online tool printout (Fig. S1c,d) was
given to 81 patients, booklets (Fig. S1e,f) to 95, and the brief deci-
sion aid to 86 (Fig. S1g). Use of the various components of the
DESIs is summarized in Table S3.
Primary outcome
The primary outcome, global QoL score, was similar between
usual-care and intervention sites at 6 months (mean difference –
0.20, 95 per cent c.i. –2.69 to 2.29; P¼ 0.900) in intention-to-treat
analysis (Table 2). QoL, was, however, better among participants
who had relevant treatment choice consultations (planned per-
protocol analysis) in the intervention arm compared with the
usual-care arm (mean difference 3.96, 0.10 to 7.82; P¼ 0.044). No
differences in QoL were evident at 6 weeks in either intention-to-
treat or per-protocol analysis.
Secondary outcomes
Treatment choice
Table 3 summarizes treatment choices by study arm. Overall,
124 of 591 patients (21.0 per cent) with an ER-positive tumour
underwent primary endocrine therapy at intervention sites,
compared with 88 of 570 (15.4 per cent) at usual-care centres
(difference 5.5 (95 per cent c.i. 1.1 to 10.0) per cent; P¼ 0.029).
Similarly, the rate of uptake of adjuvant chemotherapy was
lower among intervention sites than usual-care sites: 69 of 670
(10.3 per cent) versus 99 of 669 14.8 per cent) (difference –4.5 (–8.0
to 0) per cent; P¼ 0.013). A similar, albeit not statistically signifi-
cant, difference was evident in chemotherapy uptake among
those who had cancers with a high recurrence risk (node-positive,
high grade, ER-negative, human epidermal growth factor receptor
2-amplified, high Oncotype DX recurrence score): 66 of 267
(24.7 per cent) versus 92 of 310 (29.7 per cent) (difference –5.0
(–12.2 to 2.3) per cent; P¼ 0.183). Funnel plots for treatment
choice by site are shown in Fig. S2a (primary endocrine therapy)
and 2b (chemotherapy). These show more variation in primary
endocrine therapy rates regardless of site compared with varia-
tion in chemotherapy, but no particular pattern between the in-
tervention and usual-care sites.
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Comparison of treatment choice change compared with
historical practice
The main Age Gap cohort study within which the cRCT was
nested started recruiting in February 2013, and 19 of the 21 cRCT
intervention sites were included. The rate of primary endocrine
therapy for women with ER-positive cancers after the cRCT
intervention was compared with the historical primary
endocrine therapy rate in the Age Gap cohort study to validate
the cRCT findings. Similar analysis of chemotherapy rates was
performed.
As a post hoc analysis, the proportions of participants who
received primary endocrine therapy and chemotherapy were
compared graphically before and after starting the cRCT. At RCT
intervention sites, the proportion of patients treated with primary
endocrine therapy reduced slightly in the years before the start of
the RCT, but rose thereafter. By contrast, usual-care sites showed
modest increases (Fig. 3a,b). Little change was apparent in the up-
take of chemotherapy (Fig. 3c,d). This is in keeping with the find-
ings of the randomized intervention versus usual-care analysis.
CollaboRATE results
Of the 319 patients undergoing a consultation for choice of pri-
mary endocrine therapy versus surgery or chemotherapy versus
no chemotherapy, 148 (71 intervention, 77 usual care) completed
the CollaboRATE tool. Patients reported a high quality of shared
decision-making, with a median score of 100 in both arms
(P¼ 0.729, Mann–Whitney U test) (Table S4).
Decision regret, anxiety, and perception of cancer
Of the 396 patients offered a choice, only 85 (18.9 per cent) com-
pleted the decision regret questionnaire. Decision regret scores
did not differ significantly between usual-care and intervention
sites. The STAI was also completed by a minority of patients.
Among those who did, the scores were similar at 6 weeks and at 6
months. Similarly, the BIPQ was completed in only a small
number of consultations and scores did not differ significantly
(Table S4).
Knowledge and preferences
A total of 449 patients (209 intervention, 240 usual care)
consulted a clinician regarding surgery plus endocrine therapy
versus primary endocrine therapy alone, and 103 (27 intervention,
67 usual care) attended a consultion regarding chemotherapy.
Table S5 summarizes participant knowledge, attitudes, and
influences for 125 patients (67 intervention, 58 usual care) who
completed the knowledge and preferences questionnaires for
surgery plus endocrine therapy versus primary endocrine therapy.
The questions were answered more knowledgeably by patients in
the intervention arm (median scores 5 versus 3 of a possible 8;
P< 0.001, Mann–Whitney test U test) and a greater percentage of
participants in the intervention arm stated that they knew the
available options (94 versus 74 per cent; P¼ 0.003) and associated
advantages (91 versus 76 per cent; P¼ 0.054). There were no signif-
icant differences in the proportion of participants stating that
they knew their preferred option (96 per cent intervention, 91 per
cent usual care) or felt ready to make an informed decision
(99 versus 90 per cent) (Table S5). For questions on knowledge of
chemotherapy, the number of respondents was too small for
meaningful analysis.
Survival
Median follow-up was 36 months among participants alive at the
end of study. Survival was similar in the two arms, with an esti-
mated 2-year survival rate of just over 90 per cent in both arms
and a hazard ratio of 1.07 (95 per cent c.i. 0.80 to 1.43; P¼ 0.633)































Excluded 2 breast units
67 usual-care sites
Patients attended n = 1482
27 intervention sites
Patients attended n = 1357
Excluded n = 687
   Not eligible n = 86
   Not interested/no consent n = 322
   Treatment already started n = 101
   Clinician decision n = 42
   Treated at different site n = 44
   Administrative/lack of time n = 71
   Unable to contact/did not attend n = 71
   Not recorded n = 9
Followed up at 6 months n = 449 (21 sites)
Provided primary outcome data n = 359 (21 sites)
Excluded from analysis n = 311
   Died n = 5
   Time point not reached n = 15
   No consent to QoL analysis n = 173
   Withdrew consent for QoL analysis n = 18
   Withdrew n = 10
   Lost to follow-up/not complete n = 90
Followed up at 6 months n = 474 (25 sites)
Provided primary outcome data n = 389 (25 sites)
Excluded from analysis n = 280
   Died n = 7
   Time point not reached n = 25
   No consent to QoL analysis n = 140
   Withdrew consent for QoL analysis n = 8
   Withdrew n = 15
   Lost to follow-up/did not complete n = 85
Excluded n = 813
   Not eligible n = 97
   Not interested/no consent n = 369
   Treatment already started n = 144
   Clinician decision n = 78
   Treated at different site n = 21
   Administrative/lack of time n = 71
   Unable to contact/did not attend n = 4
   Not recorded n = 29
Excluded n = 670
   Consultation for
    primary ET/surgery n = 209
   Consultation for chemotherapy n = 29
   Consented to QoL analysis n = 489
   Completed primary QoL out
   come at baseline n = 441
Excluded n = 669
   Consultation for
    primary ET/surgery n = 240
   Consultation for chemotherapy n = 74
   Consented to QoL analysis n = 513
   Completed primary QoL out
   come at baseline n = 469
46 sites entered
Fig. 2 CONSORT diagram for the trial. (ET, endocrine therapy; QoL, quality of life).
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(94 in intervention, 90 usual care), two-thirds were unrelated to
breast cancer, giving a hazard ratio for breast cancer-specific sur-
vival of 0.88 (0.54 to 1.44; P¼ 0.609) in favour of the intervention
arm (Fig. 4b and Table 4). Sixty patients (25 intervention, 35 usual
care) experienced recurrence (hazard ratio 0.86, 0.51 to 1.43;
P¼ 0.558) (Fig. 4c). Results of survival analyses on a per-protocol
basis are shown in Fig. 4d–f.
Two women died (1 in each arm) within 30 days of surgery
(1 under local and 1 under general anaesthetic); both women
were in their 90s and death certificates cited metastatic breast
Table 1 Baseline characteristics of patients by randomized group (46 clusters or breast units)
Intervention (21 clusters) Usual care (25 clusters) Overall (46 clusters)
No. of patients 670 669 1339
Age (years)
Mean(s.d.) 78 (6) 77 (6) 78 (6)
Median (i.q.r.; range) 77 (73–82; 70–98) 76 (72–81; 69–102) 77 (70–96; 69–102)
70–74 239 (35.7) 260 (38.9) 499 (37.3)
75–79 196 (29.3) 197 (29.4) 393 (29.4)
80–84 131 (19.6) 133 (19.9) 264 (19.7)
85–89 70 (10.4) 57 (8.5) 127 (9.5)
 90 34 (5.1) 22 (3.3) 56 (4.2)
Participation level (QoL form completion)
Full (QoL forms) 489 (73.0) 513 (76.7) 1002 (74.8)
Partial (elected no QoL forms) 156 (23.3) 138 (20.6) 294 (22.0)
Consultee participation (cognitively unable to
complete QoL forms)
25 (3.7) 18 (2.7) 43 (3.2)
aPG-SGA score (nutrition) n ¼ 519 (77.5) n ¼ 565 (84.5) n ¼ 1084 (81.0)
Mean(s.d.) 1.6 (2.6) 1.1 (2.1) 1.4 (2.4)
Median (i.q.r.; range) 0 (0–2; 0–16) 0 (0–1; 0–14) 0 (0–2; 0–16)
Barthel ADL index score (frailty) n ¼ 564 (84.2) n ¼ 607 (90.7) n ¼ 1171 (87.5)
Mean(s.d.) 96.0 (10.5) 97.1 (7.7) 96.6 (9.2)
Median (i.q.r.; range) 100 (95–100; 5–100) 100 (100–100; 20–100) 100 (95–100; 5–100)
Barthel ADL index risk category (ADL score)*
No dependency (100) 408 (60.9) 479 (71.6) 887 (66.2)
Mild dependency (95) 86 (12.8) 56 (8.4) 142 (10.6)
Moderate/severe dependency ( 90) 84 (12.5) 84 (12.6) 168 (12.5)
Missing 92 (13.7) 50 (7.5) 142 (10.6)
IADL score n ¼ 538 (80.3) n ¼ 607 (90.7) n ¼ 1145 (85.5)
Mean(s.d.) 7.4(1.3) 7.5(1.2) 7.5(1.2)
Median (i.q.r.; range) 8 (7–8; 0–8) 8 (8–8; 0–8) 8 (8–8; 0–8)
IADL risk category (IADL score)*
No dependency (8) 411 (61.3) 484 (72.3) 895 (66.8)
Mild dependency (7) 69 (10.3) 61 (9.1) 130 (9.7)
Moderate/severe dependency ( 6) 83 (12.4) 76 (11.4) 159 (11.9)
Missing 107 (16.0) 48 (7.2) 155 (11.6)
CCI score n ¼ 618 (92.2) n ¼ 646 (96.6) n ¼ 1264 (94.4)
Mean(s.d.) 4.7 (1.6) 4.5 (1.5) 4.6 (1.6)
Median (i.q.r.; range) 4 (3–6; 3–11) 4 (3–5; 3–15) 4 (3–5; 3–15)
CCI risk category
0 or 1 co-morbidity 504 (75.2) 543 (81.2) 1047 (78.2)
 2 or more co-morbidities 114 (17.0) 105 (15.7) 219 (16.4)
Missing 52 (7.8) 21 (3.1) 73 (5.5)
MMSE score n ¼ 385 (57.5) n ¼ 423 (63.2) n ¼ 808 (60.3)
Mean(s.d.) 28.4(2.3) 28.0(3.0) 28.2(2.7)
Median (i.q.r.; range) 29 (28–30; 11–30) 29 (27–30; 11–30) 29 (28–30; 11–30)
Cognitive status (MMSE score)
Normal function (25–30) 593 (88.5) 578 (86.4) 1171 (87.5)
Mild impairment (20–24) 56 (8.4) 68 (10.2) 124 (9.3)
Moderate impairment (15–19) 3 (0.4) 12 (1.8) 15 (1.1)
Severe (11–14) 18 (2.7) 11 (1.6) 29 (2.2)
ECOG performance status score
0: fully active 405 (60.4) 454 (67.9) 859 (64.2)
1: restricted in physically strenuous activity 149 (22.2) 140 (20.9) 289 (21.6)
2: ambulatory and capable of all self-care 40 (6.0) 26 (3.9) 66 (4.9)
3: capable of limited self-care 25 (3.7) 19 (2.8) 44 (3.3)
4: Completely disabled 1 (0.1) 1 (0.1) 2 (0.1)
Missing 50 (7.5) 29 (4.3) 79 (5.9)
No. of medications
3 276 (41.2) 269 (40.2) 545 (40.7)
4 318 (47.5) 290 (43.3) 608 (45.4)
Missing 76 (11.3) 110 (16.4) 186 (13.9)
Values in parentheses are percentages unless indicated otherwise. * Dependency categories incorporate partially complete questionnaires where category is defined
unambiguously from completed questions. Missing data regarding cognition status were augmented with a diagnosis of dementia on the Charlson Co-morbidity
Index (CCI) score or partial/consultee participation (verified at site as indicative of dementia). QoL, quality of life; aPG-SGA, abridged Patient Generated Subjective
Global Assessment; ADL, Activities of Daily Living; IADL, Instrumental ADL; MMSE, Mini-Mental State Examination; ECOG, Eastern Cooperative Oncology Group.
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cancer as the primary cause, although a surgical contribution to
the deaths cannot be excluded.
Quality of treatment allocation
Characteristics of patients who chose primary endocrine therapy
or surgery plus endocrine therapy, and those who had chemo-
therapy or not, between between intervention and usual-care
sites did not differ significantly (Table S6).
Discussion
This large multicentre cRCT evaluated the effects of two DESIs
on clinical decision-making in older women with operable breast
cancer. In intention-to-treat analysis, use of the DESI tools did
not affect global QoL at 6 months, but the tools were intended
only for women for whom either of the relevant choices was ac-
tually offered. Preplanned per-protocol analysis of women of-
fered either choice showed a small improvement in QoL.
Treatment choices were altered, with lower rates of surgery and
chemotherapy at intervention sites. Patient knowledge was
enhanced by use of the DESIs, suggesting that they improve in-
formed decision-making.
The trial intended to recruit 50 sites, and a fixed and equal
number of participants at each site. Although it managed to ran-
domize only 46 sites, it did achieve its sample size target by
allowing differential recruitment at the randomized sites. In ad-
dition, the observed variation in the primary outcome and the
intraclass correlation coefficients were lower than anticipated in
the sample size calculation, thus preserving the power of the
trial.
The trial design included all women, regardless of whether the
tool was relevant, because treatment choice was also under
study. Consequently, clinicians were invited to use the tool to in-
form their thresholds for treatment selection, which could occur
only if the study was not limited to those ultimately offered a
choice.
Analysis of survival outcomes at a median of 36 months’
follow-up showed minimal survival difference between study
arms in intention-to-treat analysis, although the per-protocol
analysis did show some separation of the survival curves,
Table 2 Quality-of-life (global health status) at baseline, and 6 weeks and 6 months after treatment decision-making
Intervention (n ¼ 670) Usual care (n ¼ 669) Difference† ICC‡ P§
n QoL score* n QoL score*
Intention-to-treat analysis of all patients regardless of whether offered treatment choice
Baseline 441 (65.8) 74.7 (18.8) 469 (70.1) 76.0 (19.3)
6 weeks 385 (57.5) 69.2 (18.0) 425 (63.5) 69.5 (19.9) –0.23 (–2.96, 2.50) 0.00 0.868
6 months 359 (53.6) 69.0 (19.1) 389 (58.1) 68.9 (19.9) –0.20 (–2.69, 2.29) –0.01 0.900
Per-protocol analysis (only patients offered treatment choice)
Baseline 149 (22.2) 74.2 (19.8) 211 (31.5) 76.4 (18.6)
6 weeks 132 (19.7) 68.7 (16.9) 187 (28.0) 68.5 (19.6) 0.25 (–3.83, 4.33) 0.00 0.906
6 months 123 (18.4) 70.7 (17.4) 172 (25.7) 66.8 (20.1) 3.96 (0.10, 7.82) –0.01 0.044
Values in parentheses are percentages unless indicated otherwise; * values are mean(s.d.) and † values in parentheses are 95 per cent confidence intervals.
‡ Intraclass correlation coefficient (ICC): within-hospital cluster term estimated from marginal generalized estimating equations with exchangeable correlation
matrix. § Intraclass correlation coefficient test.
Table 3 Treatment choice by site
Intervention (21 clusters) Usual care (25 clusters) Overall (46 clusters) P*
Treatment decision-making: surgery versus primary endocrine thrapy
All patients 670 669 1339
Underwent consultation 209 (31.2) 240 (35.9) 449 (33.5)
Offered treatment choice 168 (25.1) 151 (22.6) 319 (23.8)
Treatment received 0.009
Surgery 526 (78.5) 547 (81.8) 1073 (80.1)
Primary endocrine therapy 124 (18.5) 89 (13.3) 213 (15.9)
Other/not treated 20 (3.0) 33 (4.9) 53 (4.0)
Patients with ER-positive disease n¼ 591 n¼ 570 n¼ 1161
Underwent consultation 197 (33.3) 215 (37.7) 412 (35.5)
Offered treatment choice 157 (26.6) 140 (24.6) 297 (25.6)
Treatment received 0.029
Surgery 451 (76.3) 459 (80.5) 910 (78.4)
Primary endocrine therapy 124 (21.0) 88 (15.4) 212 (18.3)
Other/not treated 16 (2.7) 23 (4.0) 39 (3.4)
Treatment decision-making: chemotherapy after surgery
All patients after surgery n¼ 526 n¼ 547 n¼ 1073
Underwent consultation 27 (5.1) 67 (12.2) 94 (8.8)
Offered treatment choice 21 (4.0) 56 (10.2) 77 97.2)
Received chemotherapy 69 (10.3) 99 (14.8) 168 (12.5) 0.013
High-risk patients n¼ 267 n¼ 310 n¼ 577
Underwent consultation 18 (6.7) 61 (19.7) 79 (13.7)
Offered treatment choice 17 (6.4) 53 (17.1) 70 (12.1)
Received chemotherapy 66 (24.7) 92 (29.7) 158 (27.4) 0.183
Values in parentheses are percentages. ER, oestrogen receptor. *Intraclass correlation coefficient test.
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indicating a small potential survival benefit among participants
who underwent treatment consultations as intended by the in-
tervention.
Use of the DESIs was embedded into normal practice for the
whole breast unit (cluster) and was available for use by all
women, whether or not in the trial, to ensure clinician familiarity
and enhance enrolment. In addition, the protocol was designed
to allow women to opt out of QoL and decision quality measure-
ments, in order to reduce participant burden in the older and of-
ten frail group of women who are considered candidates for
primary endocrine therapy. However, this strategy reduced the
power of the study for certain outcomes.
A number of decision tools have been developed to enhance
the quality of decision-making for patients with breast cancer
(reviewed by Nicholas and colleagues47). These have explored
various domains of care, such as type of primary surgery to
have48, whether to accept adjuvant chemotherapy49, or whether
to undergo reconstructive surgery50. None has explored the key
decision between surgery or primary endocrine therapy in older
women. Studies have shown that decision support tools can im-
prove the quality of decision-making in breast cancer. The
iCanDecide tool, for example, enhanced decision quality in
women with early-stage breast cancer relating to which type of
locoregional therapy to undergo51. Improved levels of knowledge
to support decision-making have been shown in trials52.
Although there has been a general trend by medical professionals
to reduce rates of primary endocrine therapy as new evidence is
emerging to show that this may result in inferior survival out-
comes53, the aim of a DESI is to support autonomy and informed
decision-making by the patient based on their own priorities and
wishes54. It is known that older women value QoL and mainte-
nance of independence more highly than younger women, who
value length of life most highly55.
Patients vary in their preferred level of involvement in
decision-making. Some desire passive involvement, others active
engagement, and some collaborative discussions56. Older women
tend to be slightly more passive in their decision-making than
younger patients24, but most still prefer some level of shared de-
cision-making56.
One of the limitations of the online component of the DESIs is
that it only provides data on survival metrics. Previous work by
the authors’ group has shown that older women highly value the
preservation of QoL55 and independence57, both of which are neg-
atively influenced to varying degrees by surgery58,59 and chemo-
therapy60–62. The main Age Gap cohort study63 has data on over
3400 older women in terms of the impact of these therapies on
QoL and functional capacity. It also has detailed data on adverse













































































































































a   Primary ET use intervention sites b   Primary ET use usual-care sites
c   Chemotherapy use intervention sites d   Chemotherapy use usual-care sites 
Fig. 3 Lowess smoother plots46
a,b Proportion of patients with oestrogen receptor-positive disease who had primary endocrine therapy (ET) and c,d proportion of high-risk patients after surgery
who underwent adjuvant chemotherapy, at RCT a,c intervention and b,d usual-care sites. Dashed line denotes time at which first patient recruited during RCT
phase. Blue line is the percentage of patients having the intervemtion of interest. Bandwidth 0.4 for all parts.
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nuanced outcomes will be undertaken and added to the online
tool in future to give older women a better idea of the holistic im-
pact of therapy and how it meets their priorities.
A detailed process evaluation was run alongside this study
(reported separately), which found favourable feedback from
clinicians and patients about the DESIs, but limited use by site,
and evidence about adaptations in their use that can inform
further implementation and evaluations (manuscript submitted).
Use of the DESIs in women who were offered a choice was lower
than anticipated, which in itself is an outcome from the study
and demonstrates the challenges of introducing complex inter-
ventions into clinical practice. Despite face-to-face training and a
training video on the study website, and regular contact with
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a   Ovverall survival: ITT analysis d   Ovverall survival: PP analysis
b   Cause-specific survival: ITT analysis
c   Time to recurrence: ITT analysis
e   Ovverall survival: PP analysis
f   Time to recurrence: PP analysis
Fig. 4 Overall survival, cause-specific survival and time to recurrence
Intention-to-treat (ITT) analysis of a overall survival (hazard ratio (HR) 1.07, 95 per cent c.i. 0.80 to 1.43; P ¼ 0.633), b cause-specific survival (HR 0.86, 0.54 to 1.44;
P ¼ 0.609), and c time to recurrence (HR 0.86, 0.51 to 1.43; P ¼ 0.558); per-protocol (PP) analysis of d overall survival (HR 0.81, 0.49 to 1.33; P ¼ 0.404), e cause-specific
survival (HR 0.56, 0.24 to 1.29; P ¼ 0.171), and f time to recurrence (HR 0.48, 0.17 to 1.31; P ¼ 0.150).
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numbers of staff in National Health Service clinics, staff prefer-
ences, lack of IT in consulting rooms, and security firewalls in
some Trusts’ IT systems were all implicated in this low usage.
The low response rate to some of the questionnaires relating to
decision quality metrics may also be a source of bias, with
women potentially selectively agreeing to complete these if they
had either a particularly positive or negative experience.
The online tools, booklets, and brief decision aids have been
made available openly (https://agegap.shef.ac.uk/) following
granting of UK Medicines and Healthcare products Regulatory
Agency approval. It is hoped that the DESIs will be used by clini-
cians to support shared decision-making with older women fac-
ing these two choices, that the tool will be further developed in
the future with 10-year survival and QoL outcomes, and that it
will be updated periodically to remain valid for the changing pop-
ulation demography of the UK.
The Age Gap DESIs influenced QoL and levels of knowledge
about the risks and benefits of breast cancer treatment in older
women with breast cancer. They also affected treatment selec-
tion, especially among those offered choices, suggesting that in-
formed decision-making was supported.
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